Comparative Pharmacology
Head-to-head clinical analysis: RAUDIXIN versus RAUWOLFIA SERPENTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUDIXIN versus RAUWOLFIA SERPENTINA.
RAUDIXIN vs RAUWOLFIA SERPENTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
None Documented
None Documented
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Category C
Category C
Antihypertensive
Antihypertensive